Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Price-volume action has really put a new twist on this stock. Moving up like it did on 7-8x average daily volume with no news, and on a down, pre-holiday market. As long as there aren't any dilution triggers looming, this is very bullish for this stock. I wouldn't be surpised to see this move past $3 next week, and then probably pull back as we get closer to the PDUFA date.
GLTA,
Murocman
That may be true, but I wouldn't hang with this one very long. There isn't anything on their website except a description of what the plan to do for a business model, and no information on Pinksheets.com. While I'll admit a contract with Rastelli possibly adds some validity, I can't find any third party confirmation.
Bottom line...get in quick and take profits earlier rather than later.
GLTA,
Murocman
In what timeframe? That would put the market cap over $100M with current O/S of approx 589 million. I really can't see that happening. This is a non-reporting pinksheet company. Play the momentum if it comes and at least take your original investment out and let the rest ride. To quote a very wise trader on another board, play em', don't marry em'!
GLTA,
Murocman
SFIO probably going to run short term per OTCBB alerts Board.
GLTA, Murocman
Don't forget that Advaxis is in licensing talks for its flagship vaccine. They delayed their annual meeting per the PR in late April due to the discussions. Any positive announcement regarding licensing with a major partner will make today's selloff look like a tremendous buying opportunity IMO. The question is when?
GLTA,
Murocman
Advaxis (ADXS.OB) getting attention.
This stock traded almost $1.2M in volume on almost 7.8M shares on Friday. Both are all time highs for the stock going back to 2005. It went up on no news. Somone (and not retail investors with that kind of money) was accumulating. Ophan Drug Designation by the FDA and a licensing deal are pending. Get onboard and enjoy the ride. Take profits on the way up before the money flow dries up. Make money. Don't fall in love with the stock.
GLTA,
Murocman
Follow the Money Flow
This stock traded almost $1.2M in volume on almost 7.8M shares on Friday. Both are all time highs for the stock going back to 2005. It went up on no news. Somone (and not retail investors with that kind of money) was accumulating. Ophan Drug Designation by the FDA and a licensing deal are pending. Get onboard and enjoy the ride. Take profits on the way up before the money flow dries up. Make money. Don't fall in love with the stock.
GLTA,
Murocman
ADXS up to $0.10 from $0.03 since alert
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=37142684
Up 100% on very heavy volume today. FDA Orphan drug decision due by 9 May and pending/possible licensing agreement. 52 week high is $0.14.
GLTA,
Murocman
Isn't the re-zoning just the first preliminary step? What about the whole process of getting the permits from the NRC?
The bit of reading I have done on this subject in the past indicated that was the real reason the we haven't built any new plants.
The permit process is very onerous, expensive, time consuming and slanted towards the environmentalist crowd that are simply anti-progress and use the fact that this is Nuclear power and somehow equate it to Three-Mile Island and/or Chernobyl and there's going to be tons of waste (never mind that ALL of the high level waste produced to date would fit easily in a gymnasium) and that resonates so the proposals have been killed.
Not trying to be a wet blanket, but not seeing this being re-zoned as the panacea that will make this even a $0.15 stock let alone $1. It may get there, but I think it's way too early.
JMO,
Murocman
Don't forget about earnings...hopefully after the close tomorrow. Could be a nice catalyst to sustain the run if the losses are not too bad and the outlook is positive.
GLTA,
Murocman
Meeting of Creditors on 17 June:
http://www.kccllc.net/chemtura
Didn't see this previously posted.
Murocman
ADSX had huge volume today ans was up 20%. I went back and looked at the share volume dating all the way back to 2005 and we beat the highest amount ever by a factor of 2.
Management is either using the news release from Friday as an opportunity to dilute, OR there was simply a lot of turnover/OH resistance given this stock is at it's lows and people were using the volume as a chance to get out.
It will be telling to watch the price and volume action over the next few days to see which of the above is the case.
It looks like good things may be in the offing for this company. I took a starter position today. We'll see whether it was a wise move or not.
GLTA,
Murocman
I went back and looked at the share volume dating all the way back to 2005 and we beat the highest amount ever by a factor of 2.
Management is either using the news release from Friday as an opportunity to dilute, OR there was simply a lot of turnover/OH resistance given this stock is at it's lows and people were using the volume as a chance to get out.
It will be telling to watch the price and volume action over the next few days to see which of the above is the case.
It looks like good things may be in the offing for this company. I took a starter position today. We'll see whether it was a wise move or not.
GLTA,
Murocman
ADXS on potential licensing news:
NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)-- Advaxis, Inc (ADXS). is in drug licensing discussions for its flagship vaccine construct, ADXS11-001(formerly named Lovaxin-C), in non-US markets.
Due to the potential materiality of the aforementioned event, Advaxis (ADXS) ' annual general meeting, which was scheduled for Wednesday, April 22, 2009 will be postponed and rescheduled after the licensing contract is completed.
ADXS11-001 is a therapeutic vaccine, like Dendreonâs Provenge, that treats active cancer, but much lower cost because it is not formulated for a specific patient. Unlike currently marketed prophylactic vaccines, ADXS 11-001 treats women who have already developed cervical cancer as a result of human papilloma virus (HPV) infection; the most prevalent sexually transmitted disease in the US today. Advaxis (ADXS) has already filed an IND for a Phase II trial in HPV caused cervical intraepithelial neoplasia (CIN), which is pre-cancerous.
About the ADXS11-001 Immunotherapy
Advaxisâ technology platform uses modified Listeria monocytogenes to deliver a tumor-specific antigen fusion protein. Pre-clinically, bioengineered attenuated Listeria that secrete Advaxisâ proprietary fusion protein have the ability to generate a robust immune response, break immune tolerance to cancer and produce an unusually strong and effective multi-level therapeutic immune response to existing cancer and other diseases.
Advaxisâ Listeria-based technology is based on over a decade worth of work by Dr. Yvonne Paterson in her laboratory at the University of Pennsylvania. The Companyâs proprietary antigen fusion protein technology stimulates innate immunity i.e., both arms of the adaptive cellular immune system, suppresses regulatory T-cells that inhibit many vaccines in the function of activated tumor-killing cells in addition to other anti-tumor effects.
For further information on ADXS11-001, please visit: www.advaxis.com/lc.htm.
About Advaxis, Inc. (ADXS)
Based in North Brunswick, New Jersey, Advaxis (ADXS) is developing proprietary Listeria monocytogenes (Lm) cancer vaccines based on technology developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania and chairperson of Advaxisâ scientific advisory board. Advaxis (ADXS) is developing attenuated live Lm vaccines that deliver engineered tumor antigens, which stimulate multiple simultaneous immunological mechanisms to fight cancer.
For further information on the Company, please visit: www.advaxis.com.
Forward-Looking Statements
Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Companyâs current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.
Source: Advaxis, Inc (ADXS)
Anybody have any thoughts on the fact that Chemtura had made statements about an asset sale by the end of March, but still nothing? I'm thinking maybe either they couldn't get the price they were looking for, OR business has improved such that they may be having second thoughts.
Either way, I'd expect we get a little more clarity when earnings come out, if not before.
GLTA,
Murocman
Looks like promisinng news out after the bell on Friday:
NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)-- Advaxis, Inc (ADXS). is in drug licensing discussions for its flagship vaccine construct, ADXS11-001(formerly named Lovaxin-C), in non-US markets.
Due to the potential materiality of the aforementioned event, Advaxis (ADXS) ' annual general meeting, which was scheduled for Wednesday, April 22, 2009 will be postponed and rescheduled after the licensing contract is completed.
ADXS11-001 is a therapeutic vaccine, like Dendreonâs Provenge, that treats active cancer, but much lower cost because it is not formulated for a specific patient. Unlike currently marketed prophylactic vaccines, ADXS 11-001 treats women who have already developed cervical cancer as a result of human papilloma virus (HPV) infection; the most prevalent sexually transmitted disease in the US today. Advaxis (ADXS) has already filed an IND for a Phase II trial in HPV caused cervical intraepithelial neoplasia (CIN), which is pre-cancerous.
About the ADXS11-001 Immunotherapy
Advaxisâ technology platform uses modified Listeria monocytogenes to deliver a tumor-specific antigen fusion protein. Pre-clinically, bioengineered attenuated Listeria that secrete Advaxisâ proprietary fusion protein have the ability to generate a robust immune response, break immune tolerance to cancer and produce an unusually strong and effective multi-level therapeutic immune response to existing cancer and other diseases.
Advaxisâ Listeria-based technology is based on over a decade worth of work by Dr. Yvonne Paterson in her laboratory at the University of Pennsylvania. The Companyâs proprietary antigen fusion protein technology stimulates innate immunity i.e., both arms of the adaptive cellular immune system, suppresses regulatory T-cells that inhibit many vaccines in the function of activated tumor-killing cells in addition to other anti-tumor effects.
For further information on ADXS11-001, please visit: www.advaxis.com/lc.htm.
About Advaxis, Inc. (ADXS)
Based in North Brunswick, New Jersey, Advaxis (ADXS) is developing proprietary Listeria monocytogenes (Lm) cancer vaccines based on technology developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania and chairperson of Advaxisâ scientific advisory board. Advaxis (ADXS) is developing attenuated live Lm vaccines that deliver engineered tumor antigens, which stimulate multiple simultaneous immunological mechanisms to fight cancer.
For further information on the Company, please visit: www.advaxis.com.
Forward-Looking Statements
Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Companyâs current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.
Source: Advaxis, Inc (ADXS)
Did you bother to open it? It's their de-listing from the NYSE.
GLTU,
Murocman
How likely is it that this company will sell off assets voluntarily (and soon) such that they might be able to expedite emergence from bankruptcy?
Given that the Chinese backed out at $1B, I'm thinking the onlyother folks with deep enough pockets to outbid them are the Saudi's, UAE or Qatari's.
Looking for any insight, as I'm not that familiar with what might be considered "extraneous" businesses worthy of shedding for cash.
Thanks,
Murocman
Nice recovery and good volume today. Hopefully a harbinger of the price appreciation to follow. I think this will need some contract/installation news to get the sustained volume and and price appreciation going.
Hopefully that will occur within next month?
GLTA,
Murocman
Stock up 32% today on great news and no interest? Looks like good things to come with this company.
Murocman
Anybody have any thoughts on the odds that this will make it to $0.02 sometime this week?
GLTA,
Murocman
I only entered the trade Friday at 0.0089. If I remember my three minute chart, it ran from .005 at the open up to .009, pulled back to .007, ran up .011, pulled back to .009, then ran to .014. This kind of continued all day. It was running pretty hard towards 0.02 at the end of the day. It hit the .018-.019 area about five minutes before the close and sellers took it down to the .015-.016 area.
If there isn't any news before the open, I'd expect it to pull back a bit.
Murocman
$.0.04 will be the key resistance level if this does continue to run, as that is the old high. If it does continue to push higher on Monday and approach that level, pay particular attention to how it acts. You'd be looking for strong buying volume on any pullbacks from $0.04 as a sign folks are looking to support this to higher levels IMO.
GLTA,
Murocman
I didn't say they wouldn't use embryonic stem cells. Only that it does not appear that they are, based on current and past agreements.
As I said, I also don't think the prospects of "opening" the embryonic stem cell market supports a 255% gain on almost 10x average volume. There is something specific (merger, partnership, etc.) that is brewing IMO, that has sparked the sudden interest.
Here's to a profitable trade for all of us.
Murocman
This is a different issue. As I look through the MultiCell website, their focus on adult stemcells from the liver. Adult stemcells are already in use and have shown excellent promise in multiple therapies.
Embryonic cells get more press but adult stem cells have more near-term potential.
Bottomline, I don't think the story you reference is the reason for this move. The volume is too high and the move too great. There is something else going on that the public isn't privy to yet, but obviously somebody thinks it's good news.
Murocman
I don't ever blame anyone for taking profits. You have to stay true to your strategy/style. This is about making money first and foremost.
In this case, I too like the higher plateau, and am going to hang around until the 'rest of the story becomes known', as I'm betting that will drive the price back towards the .04-.05 range.
JMO,
Murocman
I'm definitely liking the price-volume action! Just touched .014. Might see .02 today?
Murocman
Thanks, I did. I still find the price-volume action very curious given the relative quietness of the company and it's activities.
Murocman
MCET ($0.012), up 180% & on the move again
Murocman
Anybody have any thoughts on reason for the big move and volume?
It looks like this company has been (and hopefully still is) associated with several heavy-hitter pharmaceutical companies such as Merck, Bristol-Meyers, etc in the past. However it doesn't look like much has gone on in the last year+.
Given that, I don't think you'd see this kind of move and volume just over optimisim on stem cells, especially given that this company focuses on adult stem cells from the liver, which hasn't been controversial.
My thought is that there is some yet-to-be announced development that is prompting all of the action.
Anybody have anymore insight?
Murocman
MCET (.0088) Up over 100% on huge volume and no news.
Murocman
Megola Signs $50M Agreement With Vulcan Technologies for 10 Year Railroad Contract
Tuesday January 20, 4:00 pm ET
Agreement Provides for Megola to Receive $750,000 Working Capital Advance on Future Royalty Payments
POINT EDWARD, ON--(MARKET WIRE)--Jan 20, 2009 -- Megola Inc. (Other OTC:MGOA.PK - News) announced the signing of a Distribution and Sale Agency and Royalty Agreement with Vulcan Technologies, LLC, for the Hartindo line of Anti-Fire Products.
Joel Gardner, President and CEO of Megola Inc., stated, "Megola continues to move forward with its goal of bringing the Hartindo Line of Anti-Fire Products to the North American marketplace. With the successes of the advanced testing to date, we continue to demonstrate that Hartindo products are the next generation of fire inhibiting and extinguishing products from both an industry efficacy and environmental impact point of view. Attracting a company such as Vulcan shows how far reaching and lucrative the product applications can be."
Highlights of the Agreement include, but are not limited to, the following:
-- Vulcan is granted exclusive distribution/sales representative rights
for the Hartindo Product Line in the countries of Canada and Mexico
to the railroad industry (the "Railroad Industry") for a ten (10)
year term.
-- Vulcan is granted co-exclusive distribution/sales representative rights
for the Hartindo Product Line in the United States of America
(the "U.S."), to the railroad industry (the "Railroad Industry") for a
ten (10) year term.
-- In consideration of its appointments set forth in the Agreement, Vulcan
agrees to pay Megola the sum of Seven Hundred Fifty Thousand
($750,000.00) USD, as follows:
(i) a partial payment of $400,000 to Megola due five (5) business
days after the execution and delivery of this Agreement by all
parties, and;
(ii) a payment of $350,000 ninety (90) days following the date of this
Agreement.
-- Vulcan shall pay to Megola a commission payment equal to twenty-five
(25%) percent of Vulcan's profit on Hartindo Products.
-- Vulcan hereby commits to generate aggregate gross sales of the Hartindo
Products in the Railroad Industry of no less than $3 Million USD on or
before the second anniversary of this Agreement, and, thereafter,
agrees to increase such aggregate gross sales by fifteen (15%) percent
for each year thereafter, commencing with the third year of the term.
ADVERTISEMENT
About Vulcan Technologies, LLC:
Vulcan Technologies, LLC (Vulcan), incorporated in the State of New Jersey, was founded with the sole purpose of distributing a complete line of proprietary and environmentally-friendly "green" products. Vulcan's management has extensive investment banking experience and contacts in many different sectors throughout the United States and Canada, including the real estate, garment, and hospital industries, and is actively conducting business with major North American railroads. In addition to management, several Vulcan advisors have years of experience securing military, municipal and security contracts throughout North America, which will assist in establishing a substantial market presence for the Hartindo product line.
For more info on Megola Inc., please visit www.megola.com
ACCC Transmission Lines
This will be the real growth driver for this company in the next year IMO, and the turbine business will be icing on the cake if if China and the US do indeed follow through with a massive buildup in windpower.
As long as this company can stay financed, liquid and not create too much share dilution, it and the shareholders ought to do very well.
GLTA,
Murocman
WWEI being featured by HOT OTC.COM as their new big pick:
Watch List for Monday 12-1-2008
My new big pick is WWEI.
Last Monday the broader markets formed a hammer candlestick. This pattern is usually a bullish reversal pattern. Current market conditions are one of the most attractive seen in decades. I believe now is the time to put money to work.
I have no doubt that the next big industry to take off is the wind power industry. Just like how the solar industry took off 2 years ago with stocks like First Solar moving to over $300 a share!!!
WWEI is currently trading near a 52wk low which means the upside potential is very high. If WWEI was to test the high it made this past Summer the gains would be over 315% from the current levels!
WWEI is a pure wind power play with operations in China. China's consumption of energy and oil is among the top in the world.
I believe with WWEI's low price, and the growing demand for alternative energy puts WWEI in a very attractive position for investors looking for explosive growth.
The Global wind market is expected to grow by 155% from it's current size to reach 240 GW of total installed capacity by the year 2012! This will equal a total investment over the next four years of $277 BILLION!
China is the world's FASTEST growing market for Wind Energy! With an average annual growth rate of 56% for the past seven years, China's wind capacity is expected to reach 10 GW this year and 20 GW by 2010.
Even here at home, Obama has already said on tape that he wants to bankrupt the coal industry!
Start your research on WWEI by visiting: http://www.welwind.com and put it on your watch list.
I will send more information on WWEI tonight.
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.
*********************************************************
The disclaimer is to be read and fully understood before using our site, or joining our email list.
PLEASE NOTE WELL: The Hototc.com employees are not Registered as an Investment Advisor in any jurisdiction whatsoever. Full disclaimer can be read at http://www.Hototc.com/disclaimer.htm
Release of Liability: Through use of this website viewing or using you agree to hold Hototc.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Hototc.com has been compensated by WWEI fifteen thousand dollars for a one month WWEI advertising services contract. Hototc's affiliates may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. Hototc.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and Hototc.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. Hototc.com, nor any of its affiliates are not registered investment advisors or a broker dealers.
Is anybody concerned about the lack of liquidity with this stock? It looks like it will be awful tough to get into (and out of) any sizable position?
Watching for now...may take a dip in if the volume increases.
GLTA,
Murocman
Courtesy of Traceman from Yahoo THPW Board:
The overall tone of the meeting was professional and upbeat about the future. Seth Grae did the bulk of the speaking along with assistance from Tom Graham, James Guerra, Erik Hallstrom, and Maria Mastroianni as needed. All expressed extreme confidence that this company was well on track to be a major player in this industry. Botom line, THPW is on target to leverage the emerging global Nuclear Energy trends.
Consulting; Seth explained in simple terms that countries and companies are now engaging THPW instead of the other way around. The driver is their independance as compared to infrastructure type companies such as Westinghouse, GE, Areva, etc. His example; car shopping and considering a BMW vs. Lexus, and expecting the Lexus dealer to recommend a BMW because it is the right thing for the customer. Emerging countries and other countries with no nuke experience have do idea on where to start, structure themselves, which technologies to employ, which companies would be the best for infrastructure build, how to obtain financing, building transparency to win global trust, etc. THPW is the only independant company in place to execute, the only existing company to do so on safety and non-prolific stance. They are known as the only entity that can be trusted. So, private companies see this and now know it is good for their interests if they maintain a relationship with THPW. Seth made a comment along the lines that "2 years ago, who would have thought that the serious interest would initiate in the Middle East countries"? The Thorium Independance Act is a sign where the US is concerned about lagging others with this important step forward.
Technology; Overall, the Russian testing is on schedule and everything looks excellent. The post-irradation examination is going well at this point. He noted that Russia made a change to their VVER-1000 fuel approach, changing it from a 12 month cycle to 18 months. Therefore, current testing steps had to be altered to accomodate this change. Reminder, THPW is aiming at fueling VVER reactors 1st and they want to make sure their initial fuel deployment matches the same 18 month cycle. This is causing a slight delay to the current testing schedule in Russia, but no impact on the overall schedule. Slide 19 shows the schedule and when we plan to recognize technology royalties (2010-2012 timeframe). The THPW technical team has now initiated development work on deploying the technology within the AP-1000 (Westinghouse) and and EPR (Areva) reactors. Again, the Thorium Energy Independance Act opens the door for testing in our country and, again, THPW is ahead of that curve.
India; expect to hear about landing some contracts soon. I think he said by year-end, but not sure if I heard that correctly. He did say that THPW has been all over India for years, so all of the work has been done and THPW is just waiting to close deal(s). Also, the concern over the work that India has done with their thorium technology is not well founded. Their technology is complex (3 stage reactor) and produces lots of plutonium. Seth said that there is no global interest due to the complexity, cost, and proliferation concerns. This is a government founded program and we may see it used in India if at all.
Reverse split; right now the expectation is that it will happen in the 1st quarter. Seth is sensitive to concerns in this area, but he and the team is confident it must happen. He said "there is now way that we should be a penny stock at this point in time." The company is aware of institutions that want to invest and can't do so until they get on the NASDAQ.
Consulting/Advisory Service margins are at approximately 60%. The team actually thinks they can maintain this type of performace if they carefully execute timing between revenue and development expenses.
Potential; Slide 9 shows anticipated global reactor trends. The green is expected growth. Compare the green to the geen in slide 19. Then compare these 2 to the green in slide 21 to get an idea of the revenue potetntuials.
Name change; They are serious about this. A negative driver is the India government funded reactor I meantioned earler. They don't want external people to be confised about the 2 thorium technologies. The rest is obvious because the companies business plan involves more than technology. The investors that attended the meeting received a nice cross pen with the name "Lightbridge" on it. I have a pen!!!
Meeting Summary as posted by Traceman on Yahoo and re-posted here by Murocman
Been in or following this stock since Spring 07. The reason the stock price is not responding positively, is that there isn't and hasn't been anything more than promises and promissary notes up to this point. Until this company actually demonstrates that it can close a deal and generate some revenue, I think you will see more of the same with regards to the stock price.
GLTU,
Murocman
Near-Term Driver will be Potential India Consulting Deal.
The bill introduced by Senators Hatch and Reid has been referred to the Senate Energy & Natural Resources Committee. No hearing on this bill is currently scheduled on the committe calendar. The earliest this would get heard is after the election. If Congress does not come back into session, until after the New Year, we're probably looking at early Spring before this has any chance of making it onto the Floor for a vote.
That said, there looks to be a lot of potential for the company to do a deal with India very shortly after the '123' agreement is signed this weekend. This will be a new source of revenue and maybe add some priority to the bill above, given the Indian's interest in Thorium Power.
If we do get a deal with India, I'd expect to see this stock somewhere between $0.50-1.00.
Thoughts?
GLTA,
Murocman
Email from TTEG
I got an email from the company stating that CEO was returning from Asia today, and that his first day back in the office would be tomorrow. Maybe we'll see something next week?
Murocman
Just saw 25,000x$0.085 - 25,000x$0.09 on ETrade